Symic Bio

Enabling New Therapeutic Pathways
by Targeting the Extracellular Matrix

[Ameco Research @AmecoResearch]

Peripheral Arterial Disease (PAD) Therapeutics Market Status, Growth Analysis and Forecast 2018-2025
Get Full Information@ https://t.co/f5CVlKxJVn
@AstraZeneca @BayerPharma @Bristol_Myers @Merck @sanofi @SymicBio @athersys @miRagenRx @ViroMedCo

[Symic Bio @SymicBio]

Announcing close of $11M in new financing led by CIP Ventures https://t.co/tV2JS9Uzq7

[UNC-Chapel Hill AAPS @UNCCHAAPS]

Dr. John Paderi speeaking about @SymicBio at @UNCPharmacy #PharmSci #CareerDevelopment

[Manisit Das, PhD | মনীষিত দাস (he/his) @DrManisitDas]

The last professional event of @UNCCHAAPS for 2018-19 is now done & dusted. It was a fantastic year, and I am excited to be part of planning some great events. Today, we hosted Dr. John Paderi from @SymicBio, Inc at @UNCPharmacy with support from @UNC_TIBBS #PharmSci @AAPSComms

[Luke Timmerman @ldtimmerman]

Listen to @CarolynBertozzi @Stanford on her career path in science, a few cool things in glycobiology, and Legos. The Long Run podcast. https://t.co/weUNVadKbt

[Symic Bio @SymicBio]

Symic co-founder John Paderi participating in National Committee on US-China Relations' (https://t.co/KFPIg51u0j)Young Leaders Forum 2019. Local coverage here: https://t.co/ztIB4vAHoL

[Johnson & Johnson Innovation @JNJInnovation]

#ICYMI: Consensus @JLABS ‘Opportunities in China’ event: Although there are differences, there are still so many opportunities in China. All-star panel helped us finish #JPM19 strong! Thanks @SymicBio, Achelois Oncology, Qiming, LYFE Capital, Northern Light, & Sharon Chan #JLABS

[Symic Bio @SymicBio]

Congrats to Symic CSO Glenn Prestwich on being elected as an AAAS Fellow! @aaas https://t.co/d61PXXuCxW

[Symic Bio @SymicBio]

Symic Bio selected The Best of the Liver Meeting at AASLD 2018 https://t.co/vsf9RPPwEx

[Symic Bio @SymicBio]

Enjoyed presenting at #JLABS event in Beijing. Great to help build healthcare ecosystems all over the world! Thanks for the invite Sharon Chan @JNJInnovation

[Society for Vascular Surgery @VascularSVS]

PAD affects more than 10 million people in the U.S. It is more common in people who are 65 or older, but can occur at nearly any age. Get to know the symptoms of peripheral arterial disease during PAD Awareness Month: https://t.co/ekvEfjUQX2

[Foundation to Advance Vascular Cures @VascularCures]

September is vascular disease awareness month. Peripheral artery disease (PAD) is a progressive condition that affects over 8 million Americans. Learn about the risk factors and prevention at https://t.co/Dsp3hrn2eW

[Symic Bio @SymicBio]

Check out our publication on glycan therapeutics, an almost pharma-forgotten drug class!
https://t.co/WOZ06UshPD

[Symic Bio @SymicBio]

Symic Bio presentation at #ILC2018 receives "Best of ILC" recognition for preclinical liver fibrosis program: https://t.co/bm559AlOiX (see General Hepatology summary slide presentation)

[Symic Bio @SymicBio]

President and Chief Business Officer Rinko Ghosh describes clinical and preclinical development programs at the @ChinaBio Partnering Forum: matrix-targeting therapeutics for peripheral vascular disease, osteoarthritis, liver fibrosis and oncology #ChinaPartnering

[Symic Bio @SymicBio]

Symic Bio co-founder and Senior Director of Translational Biology Kate Stuart presents preclinical results from liver fibrosis candidate with matrix-targeting mechanism of action at #ILC2018; clinical development planned for 2019: https://t.co/5nQKPGZRTL

[Symic Bio @SymicBio]

12-month results from SB-030 trial demonstrate improvement in efficacy outcome; trial in prevention of vein graft failure to begin second half of 2018: https://t.co/5ed8W40hYw

[Symic Bio @SymicBio]

At the @BioCentury Future Leaders conference, CEO Ken Horne describes the broad capabilities of the Symic Bio platform and progress in the clinical development of matrix-targeting biotherapeutics

[Alyssa Panitch @alyssa_panitch]

Fantastic science &fun with #bme @UCDavisCoE grad students and @SymicBio colleagues at San Diego Glycobiology Symposium

[Symic Bio @SymicBio]

Preclinical data presented at #CRT2018 support SB-030 mechanism of action, broad applicability and the promise of a matrix biology approach. Phase 2 clinical trial in vein graft failure expected to begin in 2H18: https://t.co/WOMgXrxeYa